A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Launched by HOFFMANN-LA ROCHE · Mar 19, 2008
Trial Information
Current as of September 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 2-17 years of age
- • Systemic juvenile idiopathic arthritis with \>= 6 months persistent activity
- • Presence of active disease (\>=5 active joints, or \>=2 active joints + fever + steroids)
- • Inadequate clinical response to nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids due to toxicity or lack of efficacy
- Exclusion Criteria:
- • Wheelchair-bound or bed-ridden
- • Any other autoimmune, rheumatic disease or overlap syndrome other than systemic juvenile idiopathic arthritis
- • Intravenous long-acting corticosteroids or intra-articular corticosteroids within 4 weeks of baseline, or throughout study
- • Disease-modifying antirheumatic drugs (DMARDs), other than methotrexate
- • Previous treatment with tocilizumab
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Berlin, , Germany
Hackensack, New Jersey, United States
Cleveland, Ohio, United States
Chicago, Illinois, United States
Toronto, Ontario, Canada
Little Rock, Arkansas, United States
Cincinnati, Ohio, United States
Buenos Aires, , Argentina
Augusta, Georgia, United States
Gent, , Belgium
Leuven, , Belgium
Milano, , Italy
Barcelona, , Spain
Madrid, , Spain
Hartford, Connecticut, United States
Livingston, New Jersey, United States
Parkville, , Australia
Oslo, , Norway
Ottawa, Ontario, Canada
Valencia, , Spain
Heraklion, , Greece
Athens, , Greece
Padova, , Italy
Goeteborg, , Sweden
Ioannina, , Greece
La Plata, , Argentina
Durham, North Carolina, United States
Oklahoma City, Oklahoma, United States
Rio De Janeiro, , Brazil
Piestany, , Slovakia
Cincinnati, Ohio, United States
Vancouver, British Columbia, Canada
Westmead, , Australia
Mexico, , Mexico
Copenhagen, , Denmark
Praha, , Czech Republic
Roma, , Italy
Genova, , Italy
Liverpool, , United Kingdom
Miexico City, , Mexico
Bremen, , Germany
Lublin, , Poland
Houston, Texas, United States
Sao Paulo, , Brazil
Porto Alegre, , Brazil
Augusta, Georgia, United States
Louisville, Kentucky, United States
Louisville, Kentucky, United States
Subiaco, , Australia
Halifax, Nova Scotia, Canada
Sankt Augustin, , Germany
Utrecht, , Netherlands
Kraków, , Poland
Esplugas De Llobregat, , Spain
London, , United Kingdom
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials